The pharmaceutical company Astrazeneca said Thursday, December 23 that a third dose of its vaccine against Covid-19 "
significantly
"
increases
the level of antibodies against the Omicron variant, citing a clinical study.
Read also AstraZeneca wants to make profitable its anti-Covid vaccine
"
The levels of neutralizing antibodies Omicron after a third dose of Vaxzevria
", its anti-Covid vaccine, "
were generally similar to the levels reached after two doses against the delta variant
", details the press release.